ClinicalTrials.gg
Not yet recruitingNCT07484893Updated Mar 20, 2026

A Study to Evaluate the Safety, PK, and Immunogenicity of Recombinant Human Hyaluronidase in Healthy Subjects

A Phase 1 interventional study of recombinant human hyaluronidase in Healthy Adult Male, sponsored by Shanghai Henlius Biotech. Not yet recruiting at 1 site in China. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-20.

Sponsored by Shanghai Henlius Biotech (part of Fosun Pharma) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
Male
01

Study summary

The study is being conducted to evaluate the safety, pharmacokinetics, and immunogenicity of recombinant human hyaluronidase in healthy Chinese adult male subjects.

02

Conditions studied

  • Healthy Adult Male
03

In context

Lead sponsor

Shanghai Henlius Biotech is the lead sponsor of 132 studies on the registry; 56 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male subjects, aged ≥ 18 and ≤ 45 years.
  • (BMI) ≥ 18.0 and ≤ 28.0 kg/m².
  • Intact skin at the injection site, with no damage, tattoos, or other markings.
  • No significant medical history, or a history of abnormalities that, in the investigator's judgment, will not impact the study.
  • Physical examination, vital signs, (ECG), chest X-ray, and clinical laboratory tests are normal or abnormal without clinical significance (NCS).
  • Subjects must agree to use highly effective with their spouse or partner from the time of signing the Form (ICF) until 3 months after the last dose, or the subject is not capable of reproduction. Subjects must also refrain from sperm donation during the study and for 3 months following the last dose of the product.
  • Voluntarily signed the Informed Consent Form (ICF) prior to any study procedures, with a full understanding of the study content, procedures, and potential adverse events (AEs); and the ability to comply with the protocol requirements to complete the study.

Exclusion criteria

Exclusion Criteria:

  • History of drug abuse or or substance use, or a positive drug screen; history of long-term heavy alcohol consumption (defined as consuming more than 14 units of alcohol per week within 3 months prior to screening [1 unit = 360 mL of beer, or 45 mL of spirits with 40% alcohol content, or 150 mL of wine]) or a positive blood alcohol test; history of long-term heavy alcohol use or positive blood alcohol test; history of long-term heavy smoking (defined as an average of more than 5 cigarettes per day within 3 months prior to screening, or inability to abstain from smoking during the ).
  • Cardiac disorders, including but not limited to abnormalities during the screening period, > 450ms, or a history of clinically significant ECG abnormalities.
  • History of any clinically severe hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or oncological diseases, or allergic diseases.
  • History of upper respiratory tract infection or other acute infections within 7 days prior to the first dose, or systemic use of antibiotics within 7 days.
  • Known allergy to recombinant human hyaluronidase for injection or its formulation components; history of severe allergic reactions to any medication (e.g., angioedema); special dietary requirements or inability to comply with the standardized diet provided by the clinical site.
  • Use of any prescription drugs, over-the-counter (OTC) medications, or herbal medicines within 4 weeks prior to screening (especially salicylates, cortisone, adrenocorticotropic hormone, estrogens, or antihistamines, except for routine vitamin supplements), or within 5 half-lives of the medication (whichever is longer).
  • Vaccination within 1 month prior to administration.
  • History of blood donation or blood loss ≥ 400 mL within 3 months prior to the use of the product.
  • Participation in any other clinical study and use of investigational/control products within 3 months prior to the investigational product administration.
  • Positive for , anti-, anti-, or the syphilis spirochete test.
  • Sensory-motor disorders or autonomic movement disorders.
  • Any condition which, in the investigator's judgment, would make the subject unable to comply with the protocol requirements, instructions, or study restrictions, such as an uncooperative attitude, inability to return for follow-up visits, or inability to complete the study.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    HLXTE-HAase02, in healthy Chinese adult male subjects

    The study consists of three sequential dose-escalation cohorts, with a planned total of approximately 24 subjects (8 subjects per cohort). HLXTE-HAase02 will be administered via subcutaneous (SC) injection at a diluted concentration of 2000 U/mL. The three dose levels are 5 mL, 15 mL, and 25 mL. Each subject will receive the administration on D1 and D8. No intra-patient dose escalation is allowed. The safety of injection site reactions (ISRs) will be evaluated by the Safety Review Committee (SRC) based on their severity, incidence, and other factors to discuss the safety and determine the eligibility for escalation to the next dose level.

    Drug: recombinant human hyaluronidase

Interventions

  • HLXTE-HAase02 is a proprietary recombinant human hyaluronidase, with a molecular weight of approximately 49 kDa, is expressed in Chinese Hamster Ovary (CHO) cells and is intended for formulation development.

06

What researchers measure

Primary outcomes

  1. Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Safety Endpoint

    Time frame: From enrollment to 21 days after the second dose

  2. Incidence of hypersensitivity reactions

    Safety Endpoint

    Time frame: From enrollment to 21 days after the second dose

  3. Incidence of injection site reactions (ISRs)

    Safety Endpoint

    Time frame: From enrollment to 21 days after the second dose

Secondary outcomes

  1. Area under the concentration-time curve from time zero extrapolated to infinity (AUC0-inf)

    Pharmacokinetic (PK) parameter calculated using non-compartmental analysis (NCA) with WinNonlin version 8.2 (or higher).

    Time frame: From enrollment to 21 days after the second dose

  2. Area under the concentration-time curve from time zero to to the last measurable concentration (AUC0-t)

    PK parameter calculated using non-compartmental analysis (NCA) with WinNonlin version 8.2 (or higher).

    Time frame: From enrollment to 21 days after the second dose

  3. Maximum serum concentration (Cmax)

    PK parameter calculated using non-compartmental analysis (NCA) with WinNonlin version 8.2 (or higher).

    Time frame: From enrollment to 21 days after the second dose

  4. Time to maximum serum concentration (Tmax)

    PK parameter calculated using non-compartmental analysis (NCA) with WinNonlin version 8.2 (or higher).

    Time frame: From enrollment to 21 days after the second dose

  5. Terminal elimination half-life (T1/2)

    PK parameter calculated using non-compartmental analysis (NCA) with WinNonlin version 8.2 (or higher).

    Time frame: From enrollment to 21 days after the second dose

  6. Terminal elimination rate constant (λz)

    PK parameter calculated using non-compartmental analysis (NCA) with WinNonlin version 8.2 (or higher).

    Time frame: From enrollment to 21 days after the second dose

  7. Extrapolation percentage of AUC (%AUCex)

    PK parameter calculated using non-compartmental analysis (NCA) with WinNonlin version 8.2 (or higher).

    Time frame: From enrollment to 21 days after the second dose

  8. Positive rates of anti-drug antibodies (ADA) and neutralizing antibodies (NAb)

    Immunogenicity

    Time frame: From enrollment to 21 days after the second dose

  9. Subcutaneous injection rate (mL/min)

    Injection-related indicators

    Time frame: From enrollment to 21 days after the second dose

  10. Mean of triplicate abdominal circumference measurements

    Injection-related indicators

    Time frame: From enrollment to 21 days after the second dose

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for May 2026; primary completion for Aug 2026, 3 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 24, 2026
First posted
Mar 20, 2026
StartEst.
May 14, 2026
Primary completionEst.
Aug 25, 2026
CompletionEst.
Oct 24, 2026
Last update
Mar 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07484893
Responsible party
Sponsor
First posted
Mar 20, 2026
Start date
May 14, 2026 (estimated)
Primary completion
Aug 25, 2026 (estimated)
Completion
Oct 24, 2026 (estimated)
Last update
Mar 20, 2026

Study contacts

Qi Jin
Contact
qi_jin@henlius.com
+86 15955160489
Wei Hu
principal investigator · The Second Hospital of Anhui Medical University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Hyaluronidase (human recombinant)

Start the discussion